Search

Displaying results 1291 - 1300 of 5449 in total
  1. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    [A1351] It is effective against a wide range of Gram-positive and Gram-negative bacteria. … [L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143]

    Products: Disinfecting Wet Wipe
  2. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    Chlormadinone acetate is a progesterone derivative first synthesized in 1961. In the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens. However, the use of these drugs ...

    Mixtures: BELARA film-coated tablet 0.03mg/2mg, LUTORAL-E
  3. Drug

    Flortaucipir F-18

    go.drugbank.com/drugs/DB14914
    ApprovedInvestigational

    [A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. … [A203933, A203936, A203939] Although flortaucipir F-18 displays low levels of background binding throughout the brain,[A203936] it does display off-target binding to monoamine oxidase MAO-A and MAO-B

  4. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was … [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity

  5. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

    Products: KENGREXAL 50 MG ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 10 ADET
  6. Drug

    Poa pratensis pollen

    go.drugbank.com/drugs/DB10366
    Approved

    Poa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS329678, Treatment Set TS333938
  7. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L49231] It is the first CRISPR-based gene editing therapy to be approved in the United States. … [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS.

  8. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).

    Products: Elidel 10 mg/g Creme
  9. Drug

    Ferumoxytol

    go.drugbank.com/drugs/DB06215
    ApprovedInvestigational

    [L54506] It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively … Ferumoxytol is an intravenously administered iron preparation previously indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [

  10. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at